Iron and the response to treatment of hepatitis C

American Journal of Gastroenterology

Volumn 97, Issue 4, 2002, Pages 788-790

  Griffiths, Adrian ^a,b   Olynyk, John K ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b FREMANTLE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; IRON; RIBAVIRIN;

EDITORIAL; ERADICATION THERAPY; ERYTHROPHAGOCYTOSIS; HEPATITIS C; HUMAN; IRON BLOOD LEVEL; IRON OVERLOAD; LIPID PEROXIDATION; OUTCOMES RESEARCH; PHLEBOTOMY; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD; VIRUS PATHOGENESIS;

EID: 0036123736     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)04087-4     Document Type: Editorial

References (23)

1. Hepatitis C and iron
2. Measurements of iron status in patients with chronic hepatitis
3. Response to interferon alpha therapy is influenced by the iron content of the liver
4. Iron overload in patients with chronic viral hepatitis: How common is it?
5. Increased serum iron and iron saturation without liver iron accumulation distinguish chronic hepatitis C from other chronic liver diseases
6. Hepatic iron concentration as a predictor of response to interferon alpha therapy in chronic hepatitis C
7. Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment
8. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis
9. Diminished helper/suppressor lymphocyte ratios and natural killer cell activity in recipients of repeated blood transfusions
10. Iron overload impairs pro-inflammatory cytokine responses by Kupffer cells
11. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron
12. Beneficial effect of iron reduction therapy in patients with chronic hepatitis C who failed to repond to interferon alpha
13. Chronic hepatitis C treated with phlebotomy alone: Biological and histological outcome
14. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicentre, prospective, randomized, controlled trial
15. Iron reduction before and during interferon therapy with chronic hepatitis C: Results of a multicentre, randomized, controlled trial
16. Iron depletion is not effective in inducing a virologic response in patients with chronic hepatitis C who have failed to respond to interferon therapy
17. A pilot study of iron depletion as adjuvant therapy in chronic hepatitis C patients not responding to interferon
18. Effect of iron depletion on long term response to interferon alpha in patients with chronic hepatitis C who previously did not respond to interferon therapy
19. Retreatment of hepatitis C interferon non-responders with larger doses of interferon with and without phlebotomy
20. A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C
21. Hepatic iron overload does not prevent a sustained virological response to interferon-a therapy: A long term follow-up study in hepatitis C-infected patients with β thalassemia major
22. Effect of iron overload on the response to recombinant interferon-alpha treatment in transfusion dependent patients with thalassaemia major and chronic hepatitis C
23. Long term efficacy of alpha-interferon treatment in beta-thalassemics with chronic hepatitis C